Skip to main content

HB 1223 — Louisiana

ECONOMIC DEVELOPMENT: Establishes the Louisiana Clinical Trial Competitiveness and Patient Access Act

Signed into law 2026 session House

This page lists STATE bills only. Open States, our source for this data, tracks state legislatures -- it has no visibility into city councils, county commissions or school boards. We don't yet have a free, storable source for local measures; see the About page for why.

Summary

  • HB 1223 is a bill in the Louisiana House, 2026 session, introduced March 31, 2026.
  • Sponsored by Jack McFarland.
  • Current status: signed into law.
  • Most recent action (June 9, 2026): Signed by the Governor. Becomes Act No. 886.
  • 3 recorded votes; the most recent, on May 29, 2026, passed 98-0.

Contact your legislator about this bill

Bill text & documents

Sponsors

Primary: Jack McFarland

History

  1. Introduced, completed
  2. Passed House, completed
  3. Passed Senate, completed
  4. Sent to Governor, completed
  5. Signed into law, completed, current stage
  1. House Read by title. Lies over under the rules.
  2. House Read by title, under the rules, referred to the Committee on Commerce.
  3. House Reported with amendments (12-0).
  4. House Read by title, amended, ordered engrossed, passed to 3rd reading.
  5. House Scheduled for floor debate on 04/27/2026.
  6. House Scheduled for floor debate on 05/05/2026.
  7. House Notice given.
  8. House Read by title, returned to the calendar.
  9. House Scheduled for floor debate on 05/07/2026.
  10. House Notice given.
  11. House Read by title, returned to the calendar.
  12. House Called from the calendar.
  13. House Scheduled for floor debate on 05/11/2026.
  14. House Notice given.
  15. House Read by title, returned to the calendar.
  16. House Called from the calendar.
  17. House Read third time by title, amended, roll called on final passage, yeas 94, nays 0. Finally passed, title adopted, ordered to the Senate. Milestone

    FINAL PASSAGE (#1141): 94 yes 0 no, 11 other Passed, 100% yes

  18. House Called from the calendar.
  19. Senate Received in the Senate. Read first time by title and placed on the Calendar for a second reading.
  20. Senate Read second time by title and referred to the Committee on Commerce, Consumer Protection and International Affairs.
  21. Senate Reported with amendments.
  22. Senate Committee amendments read and adopted. Read by title and referred to the Legislative Bureau.
  23. Senate Reported without Legislative Bureau amendments. Read by title and passed to third reading and final passage.
  24. House Received from the Senate with amendments.
  25. Senate Rules suspended. The amended bill was read by title, passed by a vote of 38 yeas and 0 nays, and ordered returned to the House. Motion to reconsider tabled. Milestone

    FINAL PASSAGE (#1354): 38 yes 0 no, 1 other Passed, 100% yes

  26. House Scheduled for concurrence on 05/29/2026.
  27. House Read by title, roll called, yeas 98, nays 0, Senate amendments concurred in.

    CONCUR IN SENATE AMENDMENTS (#1713): 98 yes 0 no, 7 other Passed, 100% yes

  28. House Enrolled and signed by the Speaker of the House.
  29. Senate Signed by the President of the Senate.
  30. House Sent to the Governor for executive approval.
  31. House Effective date: 06/09/2026.
  32. House Signed by the Governor. Becomes Act No. 886. Milestone Latest

Source: Open States. Last checked November 3, 2026. How we keep this accurate ›